Detailed Information on Publication Record
2021
Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States
RIAD, Abanoub, Andrea POKORNÁ, Mohamed MEKHEMAR, Jonas CONRAD, Jitka KLUGAROVÁ et. al.Basic information
Original name
Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States
Authors
RIAD, Abanoub (818 Egypt, guarantor, belonging to the institution), Andrea POKORNÁ (203 Czech Republic, belonging to the institution), Mohamed MEKHEMAR, Jonas CONRAD, Jitka KLUGAROVÁ (203 Czech Republic, belonging to the institution), Michal KOŠČÍK (203 Czech Republic, belonging to the institution), Miloslav KLUGAR (203 Czech Republic, belonging to the institution) and Sameh ATTIA
Edition
Vaccines, Basel, MDPI, 2021, 2076-393X
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30102 Immunology
Country of publisher
Switzerland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 4.961
RIV identification code
RIV/00216224:14110/21:00121806
Organization unit
Faculty of Medicine
UT WoS
000666000500001
Keywords in English
AZD1222; ChAdOx1 nCoV-19; COVID-19; Czech Republic; drug-related side effects and adverse reactions; Germany; health personnel; mass vaccination; Oxford–AstraZeneca vaccine
Tags
International impact, Reviewed
Změněno: 8/2/2022 10:32, Mgr. Tereza Miškechová
Abstract
V originále
Recent reports of thrombosis following AstraZeneca COVID-19 vaccine in young females (<55 years-old) led to temporary suspension and urgent investigation by the European Medicines Agency (EMA) that concluded that vaccine benefits still outweigh its side effects (SEs). Therefore, this study aims to provide early independent evidence on the vaccine SEs’ prevalence and their potential risk factors; a cross-sectional survey-based study was carried out between February and March 2021 in Germany and Czech Republic among healthcare workers who recently received the AstraZeneca COVID-19 vaccine. The study used a validated self-administered questionnaire composed of twenty-eight multiple-choice items covering demographic variables, medical anamneses, and local, systemic, oral, and skin related SEs of the vaccine. Out of the ninety-two included participants, 77.2% were females and 79.3% were from Germany. Their mean age was 35.37 ± 12.62 (19–64) years-old, 15.2% had chronic illnesses and 22.8% were receiving medical treatments. Overall, 94.6% of the participants reported at least one SE. The most common local SE was injection site pain (72.8%), and the most common systemic SEs were fatigue (73.9%), muscle pain (55.4%), chills (48.9%), feeling unwell (46.7%), nausea (45.7%), and headache (29.3%). The vast majority (91.9%) resolved within 1–3 days, and the below 35 years-old group was the least affected age group. The SEs’ frequency was insignificantly higher in females and previously infected participants; the vaccine safety for the elderly was supported by the early findings of this study. Chronic illnesses and medical treatments were not associated with an increased risk of SE incidence and frequency. No blood disorder SEs were reported in our sample. Further independent studies are highly required to evaluate the safety of the AstraZeneca vaccine and to explore whether gender or previous infection could be associated with the vaccine SEs.
Links
| CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód MU (CEP code: EF16_013/0001826) |
| ||
| LTC20031, research and development project |
| ||
| MUNI/A/1608/2020, interní kód MU |
| ||
| MUNI/IGA/1543/2020, interní kód MU |
| ||
| 90128, large research infrastructures |
|